Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine 104-week trial in 3,297 high-risk T2DM patients showed semaglutide reduced composite MACE by 26% versus placebo establishing cardiovascular benefit for GLP-1 receptor agonists
In comparison, the injectable version of Wegovy led to an average weight loss of 15% of body weight after 68 weeks in a previous study, according to the company
The economic calculus changes if insurance does not cover brand-name semaglutide
Through its effects on appetite, digestion, and blood sugar control, it allows patients to achieve meaningful weight loss in a safe and controlled way
US$ 28.48
US$ 20.10
US$ 23.38
US$ 28.82
US$ 27.90
US$ 22.57
US$ 24.10
US$ 26.10
